Ignite Creation Date:
2024-05-06 @ 11:18 AM
Last Modification Date:
2024-10-26 @ 12:43 PM
Study NCT ID:
NCT03483324
Status:
COMPLETED
Last Update Posted:
2022-05-31
First Post:
2018-03-23
Brief Title:
Trial of AB-110 in Adults With Hematologic Malignancies Undergoing Cord Blood Transplantation
Sponsor:
Angiocrine Bioscience
Organization:
Angiocrine Bioscience
Study Overview
Official Title:
A Phase 1 Open-Label Multi-Center Trial of AB-110 in Adults With Hematologic Malignancies Undergoing Cord
Status:
COMPLETED
Status Verified Date:
2022-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
A phase 1b open label multi-center trial of AB-110 in adults with hematologic malignancies including acute myeloid leukemia AML acute lymphoblastic leukemia ALL and myelodysplasia MDS undergoing cord blood transplantation Subjects will receive unmanipulated cord blood UCB and AB-110 expanded CD34 enriched hematopoietic progenitor cells HSPC
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None